Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BEAM with free AI briefings, catalyst countdowns, and dilution alerts.

BEAM · Beam Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1B Cash on Hand
35.4mo Cash Runway
Follow BEAM by email Get an email when BEAM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BEAM, unsubscribe in one click. Privacy

📣 What BEAM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ristoglogene Autogetemcel (BEAM-101) Sickle Cell Disease Phase 1/2 · NCT05456880 Active not recruiting
Allogeneic Anti-CD7 CAR-T Cells BEAM-201 Lymphoblastic Lymphoma Phase 1/2 · NCT05885464 Active not recruiting
BEAM-301: Single dose of BEAM-301 administered… Glycogen Storage Disease Type Ia Phase 1/2 · NCT06735755 Recruiting
BEAM-302 Alpha 1-Antitrypsin Deficiency Phase 1/2 · NCT06389877 Recruiting
Allogeneic Anti-CD7 CAR T Cells T-Cell Acute Lymphoblastic Leukemia/Lymphoma Phase 1 · NCT06934382 Active not recruiting
BEAM-103 Healthy Subjects Phase 1 · NCT07304791 Recruiting
Long-Term Follow-up Study of patients who… Hemoglobinopathy N/A · NCT07373639 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BEAM holds $1B in cash and short-term investments (as of Sep 30, 2026) and burns about $88.4M/quarter from operations, an estimated runway of 35.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BEAM files for a raise →

👥 Who Owns BEAM

Insiders 3.3% Other 5%+ holders 9.8% Institutions (394 holders) 86.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
ARK Investment Management LLC Institution (13G, 5%+) 11,805,372 11.41% 2026-09-30
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 10,282,210 9.93% 2026-06-30
Dapice Joshua J. 5%+ holder (13G) 10,141,856 9.80% 2025-12-31
STATE STREET CORPORATION Institution (13G, 5%+) 5,228,529 5.05% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 5,122,475 4.95% 2026-03-31
FMR LLC
10% owner
Insider 1,695,828 1.64% 2026-06-25
John M. Evans
CEO, Director · +335,813 options
Insider 1,150,205 1.11% 2026-10-15
Giuseppe Ciaramella
President · +534,259 options
Insider 253,911 0.25% 2026-09-24
Christine Bellon
Chief Legal Officer · +40,000 options
Insider 109,711 0.11% 2026-04-01
Sravan Kumar Emany
Chief Financial Officer · +63,500 options
Insider 105,456 0.10% 2026-03-31
Amy Simon
Chief Medical Officer · +88,500 options
Insider 85,696 0.08% 2026-07-27
Bethany J Cavanagh
SVP, Finance and Treasurer · +40,000 options
Insider 50,984 0.05% 2026-10-01

Share count 103,495,644 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BEAM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BEAM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.